Tilray (TLRY) Medical announced the expansion of its Tilray Craft portfolio in Germany with five new cannabis flower products produced in Germany at Tilray’s EU-GMP certified facility in Neumunster as part of the BfArM in-country cultivation program. The additions reflect Tilray’s ongoing commitment to providing physicians and pharmacies with a diverse range of quality, EU-GMP certified medical cannabis options for eligible patients. Tilray Craft cannabis is cultivated and produced indoors at Tilray’s EU-GMP certified facility located in Neumunster, Germany. The production process adheres to rigorous quality control standards and protocols, ensuring distinctive, quality medical cannabis that patients can depend on for consistency and reliability. New Tilray Craft Products: Tilray Craft Cannabisbluten THC30 TRM; Tilray Craft Cannabisbluten THC28 TRM; Tilray Craft Cannabisbluten THC28 PPV; Tilray Craft Cannabisbluten THC25 PPV; Tilray Craft Cannabisbluten THC22 SNS. All Tilray Craft products are available by prescription at pharmacies throughout Germany.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLRY:
- EA acquired in go-private deal for $55B, Carnival reports Q3 beat: Morning Buzz
- Unusually active option classes on open September 29th
- Video: Merus jumps after deal to be bought, MoonLake sinks after trial data
- Cannabis Stocks Jump as Trump Endorses Cannabidiol for Elderly Care
- Morning Movers: Tilray rises as Trump touts CBD benefits for seniors